COVID-19-positive cancer patients undergoing active anticancer treatment

Jamshed, Ali; Sajjad, Kashif; Farooqi, Amer; Aziz, Muhammad Tahir; Rahat, Ayesha; Khan, Sarah

doi:10.1016/j.hemonc.2020.12.001

Cited by 7 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been observed in a Tertiary Care Hospital at Lahore that the mortality rate in COVID-19 cancer patients at 30 days is higher among patients with additional risk factors such as old age, metastatic disease, and palliative intent anticancer treatment received in the preceding 4 weeks of COVID-19 infection. Their study did not reveal higher COVID-19-related mortality in cancer patients undergoing active anticancer treatment in a developing country, comparable to existing evidence from developed countries, despite limited resources [21].…”

Section: Discussionmentioning

confidence: 47%

Incidence and Outcome of COVID-19 Infection in Cancer Patients, A Long Term Study: An Experience From Pakistan

Rasheed¹,

Vallacha²,

Malik³

et al. 2022

IJCEMR

View full text Add to dashboard Cite

Introduction:Cancer patients are at risk of severe symptoms because of COVID 19 virus. Cancer patients are prone because they are immune-comprised due to their cancer and due to treatment with chemotherapy/immunotherapy. It is difficult to treat cancer patients in this pandemic due to limited data. Incidence of severe complications related to this virus in cancer patients is high then non cancer patients of same age group. They need more ICU admission and invasive ventilation. Since clinical data is relatively scarce in this perspective. This study is being carried out to perceive incidence and severity and outcome of this viral infection in cancer population in under developed country. Methods: All cancer patients who were receiving active oncological treatment and on surveillance visited the oncology clinic or required inpatient hospital care were included in this study. Aim was to assess the incidence and outcome of COVID 19 infection in oncology patients treated in our institute. Files of all adult cancer patients who were COVID positive and required inpatient care or managed at home from March 2020 till March 2021 were reviewed retrospectively. Purposive non-random sampling has been used for sampling technique. All details related to this infection have been recorded on a predesigned Proforma. Results: Total number of patients who visited Oncology clinics during 1 st wave and 2 nd wave of covid-19 were: n-7877 [M :F-1.5 :1]. During these waves total oncology patients who contracted COVID virus were: N= 170[170/ 7877=2.1 %, M: F-1.8: 1]. Only n-18 patients expired, Mortality according to severity of infection was: mild [4.7%], moderate [1.7%] and severe [4.1%]. More patients died secondary to this virus were urinary bladder [22.8%] and prostate cancer [15%] followed by GI [11.5%]. Patients with mild infection died because they had associated sepsis and uncontrolled malignancy. Mortality according to age, total [n-18], 5, 5, 8, and 0 according to age group 1, 2, 3 and 4. Mortality with co-morbidities, only chronic kidney disease [n-03], only hypertension [n-4], only ischemic heart disease [n-0], with multiple co-morbidities Afshan Asghar Rasheed et al.

show abstract

Section: Discussionmentioning

confidence: 47%

Incidence and Outcome of COVID-19 Infection in Cancer Patients, A Long Term Study: An Experience From Pakistan

Rasheed¹,

Vallacha²,

Malik³

et al. 2022

IJCEMR

View full text Add to dashboard Cite

show abstract

“…However, after adjustment for confounding factors, we found no signi cant association between comorbidities and risk of Covid-19 death among cancer patients. Although limited studies supported our ndings [33], most studies have shown an association between comorbidities and excess risk of severe outcomes [34].…”

Section: Discussionmentioning

confidence: 52%

Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran

Seyyedsalehi

Rahmati

Ghalehtaki

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Data on COVID-19 outcomes in cancer patients from low- and middle-income countries is limited. We conducted a large study about the mortality rate of COVID-19 in cancer patients in Iran. Methods: We obtained clinical characteristics and outcomes of COVID-19 in cancer and non-cancer patients. Based on logistic regression models, the odds ratios (ORs) and 95% confidence intervals (CIs) for hospital death and 60-day mortality of cancer patients were estimated. Results: The cancer patients had higher ICU admission (35.8% vs. 26.6%) and intubation (25.4 vs. 11.6%) than non-cancer patients. Hospital mortality was higher in cancer patients (37.2%) than in non-cancer patients (15.2%) (OR = 4.56, 95% CI 3.51-5.93). Among cancer patients, mortality rates of the lung (OR = 1.57) and colorectal (OR = 1.50) cancers were higher than other cancer patients, albeit these associations were not statistically significant. The risk of 60-day mortality was significantly higher in lung cancer (OR = 1.75, 95% CI 1.04-2.93). The risk of COVID-19 death was higher in cancer patients who had an oxygen saturation less than 85% (OR = 1.79, 95% CI 1.20 -2.69), were on active treatment (OR = 1.94, 95% CI 1.43-2.6), or had metastasis (OR = 3.32, 95% 2.30-4.79) during the COVID-19 infection. Conclusion: COVID-19 mortality was higher in cancer patients, especially with active disease and metastatic. Among others, lung cancer patients experience the worst prognosis from COVID-19 infection. The excess risk of death after discharge from the hospital suggests providing follow-up care for cancer patients after discharge from a COVID-19 hospitalization.

show abstract

“…In sequence, 59 studies were excluded because of not reporting useful data for the analysis, reviews, case reports, non-consecutive or case series, or were on only hematological cancers and we failed to contact their corresponding authors. Finally, a total of 14 studies 12 , 14 , 36 , 37 , 38 , 39 , 15 , 20 , 30 , 31 , 32 , 33 , 34 , 35 with a total 3,770 infected cancer patients and 685 hematological cancer cases with COVID-19 were ultimately found to be eligible for inclusion. The main characteristics of the selected studies are presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“… 4 , 12 , 13 Recent publications have indicated an increased risk of severe infection, poorer outcomes and worse prognosis in infected cancer patients. 14 , 15 , 16 , 17 , 18 More importantly, cancer patients with the SARS-CoV-2 infection had a higher risk of severe events, such as requiring invasive ventilation and death, than infected patients without cancer. 19 The United Kingdom Coronavirus Cancer Monitoring Project (UKCCMP) showed that cancer patients with the SARS-CoV-2 infection with advanced age and with other comorbidities had a significantly higher mortality rate.…”

Section: Introductionmentioning

confidence: 99%

“…Several epidemic and clinical studies have been consulted on patients with hematologic malignancies in different population mortalities in order to understand the epidemiology of COVID-19. 14 , 19 , 25 There are few data on the risk of developing COVID-19 in hematological cancer patients. 25 However, those studies results were not inconclusive and data on the proportion of hematological cancer patients with the SARS-CoV-2 infection are lacking.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic: A systematic review and meta-analysis

Jafari

Dastgheib

Ferdosian

et al. 2022

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Introduction The coronavirus disease-2019 (COVID-19) has emerged as a novel infection which has spread rapidly across the globe and currently presents a grave threat to the health of the cancer patient. Objective The aim of this meta-analysis was to evaluate the proportion of hematological cancer patients with the SARS-CoV-2 infection during the COVID-19 pandemic. Method A comprehensive literature review was performed on PubMed, Web of Science, Scopus, EKB SciELO, SID, CNKI and Wanfang databases to retrieve all relevant publications up to January 31, 2021. Observational studies, consecutive case-series and case-control studies were included. The proportion for hematological cancer patients with COVID-19 was estimated using the odds ratios (ORs) and 95% confidence interval (95% CIs). Results Fourteen studies with a total of 3,770 infected cancer patients and 685 hematological cancer cases with COVID-19 were selected. Combined data revealed that the overall proportion of hematological cancer patients with COVID-19 was 16.5% (95% CI 0.130 - 0.208, p ≤ 0.001). The stratified analysis by ethnicity showed that the proportion was 18.8% and 12.4% in Caucasian and Asian hematological cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that its proportion was the highest in the United Kingdom (22.5%), followed by France (17.1%) and China (8.2%). Conclusion This meta-analysis result indicated that the proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 16.5%. Further larger sample sizes and multicenter studies among different ethnic groups are necessary to get a better assessment of the proportion.

show abstract

COVID-19-positive cancer patients undergoing active anticancer treatment

Cited by 7 publications

References 12 publications

Incidence and Outcome of COVID-19 Infection in Cancer Patients, A Long Term Study: An Experience From Pakistan

Incidence and Outcome of COVID-19 Infection in Cancer Patients, A Long Term Study: An Experience From Pakistan

Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran

Proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic: A systematic review and meta-analysis

Contact Info

Product

Resources

About